|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86.95 SEK | -1.25% |
|
-4.76% | -19.57% |
| 06-14 | Enveda Therapeutics, Inc. announced that it has received $55 million in funding from a group of investors | CI |
| 06-05 | Kinnevik AB Approves Extra Distribution | CI |
Transcarent, Inc. announced that it will issue 7,325,631 series D preferred shares at issue price of $20.47605 per share for the gross proceeds $149,999,986.63755 in funding on March 7, 2024. The shares are convertible, and non-redeemable. The shares will be convertible in common shares at a price of $20.47605 per share.
The preferred shares have a par value of $0.00001 per share.
| 1st Jan change | Capi. | |
|---|---|---|
| -19.57% | 2.33B | |
| +24.28% | 83.11B | |
| +59.94% | 17.34B | |
| +9.11% | 17.33B | |
| +9.64% | 14.52B | |
| -4.41% | 12.3B | |
| +11.19% | 11.27B | |
| -0.70% | 10.93B | |
| +33.84% | 10.08B | |
| +90.11% | 9.92B |
KINNEVIK AB 
